Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT)...

Area of Science:

• Cardiology
• Pharmacology
• Hypertension Research

Background:

• Patients with resistant hypertension (TRH) face elevated cardiovascular risks.
• Current research often prioritizes blood pressure reduction over hard cardiovascular endpoints.
• The efficacy of intensive lipid lowering in TRH patients remains understudied.

Purpose of the Study:

• To investigate the impact of intensive lipid lowering on cardiovascular event reduction in patients with resistant hypertension.
• To assess the effectiveness of high-dose atorvastatin in this high-risk cohort.

Main Methods:

• A substudy of the Treating to New Targets trial involving 10,001 patients with coronary artery disease and LDL cholesterol <130 mg/dL.
• Randomization to atorvastatin 80 mg versus 10 mg.
• TRH defined by specific blood pressure and antihypertensive medication criteria; median follow-up of 4.9 years.

Main Results:

• 11.1% of patients (1112) had TRH.
• Atorvastatin 80 mg significantly reduced the primary composite outcome of major cardiovascular events (HR=0.70, P=0.01) in TRH patients.
• This reduction was driven by decreased coronary heart disease deaths and major coronary events, with a trend towards reduced all-cause mortality.

Conclusions:

• Intensive lipid lowering with atorvastatin 80 mg provides significant cardiovascular event reduction in patients with resistant hypertension.
• High-dose atorvastatin may be a valuable therapeutic option for managing cardiovascular risk in this population.